Pharma R&D World Asia 2011, Singapore
.
Monday 7th February 2011 to Tuesday 8th February 2011
Singapore, -
£650.00/Industry delegate
 Roundtable Discussions
- R&D Strategies – Partnership and Alliances
- Clinical Development and Outsourcing
Day One: Stream 1 - R&D Strategy, Business Development and Global Partnership
- Regulation and Outsourcing in China, Japan, Korea, India, Singapore
- Integrating services and partnership for Drug Discovery
- Discovery Strategies in Diabetes, Inflammatory and Infectious Therapies
Day Two: Stream 1- Discovery and Development Strategies in Different Therapeutic areas, Biomarkers, Translational Medicine, Molecular Profiling (PART B)
- Drug Discovery in Oncology and other Therapeutic Approaches
- Biomarker Discovery and Development
- Translational Medicine- Biomarkers, Molecular Profiling to Clinical trials
Day One: Stream 2 Discovery and Development of Biologics, Antibodies and Proteins
- Discovery and Production of Biologics
- Antibody Discovery
- Roundtable- Biologics Franchise
- Preclinical Development Outsourcing strategies
Day Two: Stream 2 Clinical Development and Clinical Trial Management
- Outlook Clinical Development and Outsourcing
- Drug Development activities in Asia
- Clinical Trials Outsourcing
- Patient Recruitment to Sample Data Analysis
Technology Workshops - A series of one hour workshops
Stream One - Screening. Assay Development, Microarray Technology, Metabolomics, Molecular Profiling, Biomarkers in Discovery and Clinical Development, Imaging
Stream Two – Clinical Trail Management, E-submission, Trail monitoring and project management, Data management, Safety reporting, Central laboratory services.
|
|
|
|
| Hear insights and views from our leading line up of industry experts: |
|
|
|
Dr Suchitra Kataria, Head Business Development and In-Licensing - Regional Strategic Development Asia Pacific, Bayer Schering, Singapore
|
|
|
|
Dr Greg Tucker-Kellogg, Cheif Technology Officer and Senior Director, Lilly Singapore Centre for Drug Discovery (Eli Lilly)
|
|
|
|
Dr Alain van Gool, Head Molecular Profiling, Translational Medicine Research Centre Singapore, Schering Plough
|
|
|
|
Dr Miro Venturi, Director Biomarker and Experimental Medicine, Roche Pharma Development
|
|
|
|
Alex Liu, Chairman, Golden Biotechnology Corp, Taiwan
|
|
|
|
Dr Sudhir Sahasrabudhe, CEO, Prolexys Pharmaceuticals Inc.
|
|
|
|
Dr Pele Chong, Distinguished Investigator and Director, Vaccine R&D Center, NHRI, Taiwan
|
|
|
|
Dr. Xin Ma, Head of Global Drug Discovery - Innovation Center China Bayer Schering Pharma
|
|
|
|
Stella Xu, Executive Director, Roche Pharma Partnering, China
|
|
|
|
Michael Shi, Director, Biomarker Project Leader Exploratory Oncology Development, Novartis
|
|
|
|
Deborah Hartman, Vice President, Respiratory and Inflammation Research Astrazeneca Charnwood, Astrazeneca
|
|
|
|
Shintaro Nishimura, Vice President, Bioimaging Research Laboratories, Astellas Pharma Inc. Astellas Japan
|
|
|
|
Dr Jingsong Wang, Director of Discovery Medicine & Clinical Pharmacology, Bristol-Myers
|
|
|
|
Dr. Erik Sprengers, Site Head, Schering-Plough, Singapore
|
|
|
|
Dan Zhang, CEO, Fountain Medical Development Ltd.
|
|
|
|
Angela Dunne, Principal Scientist, GlaxoSmithKiline, Singapore
|
|
|
|
Prof Uros Urleb, Global Product Development, Chief Scientific Officer, Sandoz International HmbH
|
|
|
|
Swami Subramaniam, Director, Licensing and External Research, India, merck Sharp and Dohme
|
|
|
|
Dr. Li Dong Bei, Director of Bioanalytical Services Dept., WuxiApptec, China
|
|
|
|
Li Chen, Chief Scientific Officer, Roche R&D Center (China) Ltd
|
|
|
|
Dr Bradley Marchant,q Head of Clinical Development Asia, Pfizer Emerging Markets, Shanghai, China
|
|
|
|
Dr Phil Kearney, Director Licensing and External Research, Aust/NZ, Singapore and Malaysia, Merck Sharp & Dohme, Australia
|
|
|
|
Dr Daniel Grant, Director, Asia R&D Business Development, Australia, New Zealand, Singapore, Pfizer Australia
|
|
|
|
Dr Jack Aurora, Chief Scientific Officer, Generic Drugs, Hisun Pharma (Hang Zhou) Co. Ltd, China
|
|
|
|
Dr Ming Wang, Scientific Director, Metabolic Disorders, Amgen, Inc.
|
|
|
|
Dr Jeanette M. Wood, Head of Biology, S*BIO Pte Ltd, Singapore
|
|
|
|
Jurgen Moll, Director, Department of Cell Biology, Oncology, Nerviano Medical Sciences Srl.
|
|
|
|
|
|
|
|
|
Event Agenda
